Study Finds Ravulizumab Effective in Treating Acetylcholine Receptor–Positive Generalized MG
July 2nd 2024More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG activities of daily living scores.
Read More
Insurers continue to raise consumer costs despite covering fewer drugs and having more drug coverage restrictions; the Biden Administration is investing hundreds of millions of dollars to train geriatricians; the Federal Trade Commission has opened an investigation into Teva Pharmaceuticals after the company refused to take down patents for its asthma and chronic obstructive pulmonary disease inhalers.
Read More
Advancements and Challenges in Treating Relapsed/Refractory Multiple Myeloma
July 2nd 2024In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.
Read More
AAV Therapy: A Successful 1-Patient SPG50 Gene Therapy Trial
July 1st 2024An adeno-associated virus (AAV) gene therapy for hereditary spastic paraplegia type 50 (SPG50)—funded by a young patient’s family—gives hope not only to a 4-year-old, but to researchers working on similar projects for other rare diseases.
Read More
131 Million Americans Live in Areas With Dangerous Air Pollution Levels, Report Finds
July 1st 2024Based on the 2024 State of the Air report, Munaf Siyamwala, MD, of Centerpoint Medical Center, noted that patients with COPD need personalized action plans to manage flare-ups exacerbated by poor air quality and extreme weather conditions.
Read More
Survey Shows Suboptimal Comfort in Treating Hair Among Patients With SOC
July 1st 2024In addition to ensuring residency programs provide educational and practical opportunities for addressing skin of color (SOC) hair-related concerns, prioritizing having residents of diverse backgrounds can help close knowledge and comfort gaps, suggest researchers.
Read More
ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL
July 1st 2024The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.
Read More
Lasers Offer New Options for Hair Loss Treatment in Alopecia Management
June 29th 2024Various laser technologies are emerging as a promising treatment for alopecia, showing effectiveness in hair regrowth with minimal adverse events. These treatments target inflammation and stimulate hair follicles to promote hair growth, but more research is necessary to confirm long-term safety and efficacy for some lasers.
Read More